Emergent BioSolutions

$90.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$4.48 (-4.73%) As of 6:36 PM UTC today

Why Robinhood?

You can buy or sell EBS and other stocks, options, and ETFs commission-free!

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD. The listed name for EBS is Emergent Biosolutions, Inc.

CEO

Robert G. Kramer

Employees

2,200

Headquarters

Gaithersburg, Maryland

Founded

1998

Market Cap

4.64B

Price-Earnings Ratio

17.51

Dividend Yield

—

Average Volume

915.63K

High Today

$94.78

Low Today

$89.90

Open Price

$93.01

Volume

430.88K

52 Week High

$137.61

52 Week Low

$46.37

EBS News

CNBC18h

Emergent BioSolutions says it can make 1 billion Covid vaccine doses annually

As the U.S. makes headway in its coronavirus vaccination campaign, Emergent BioSolutions CEO Bob Kramer appeared on CNBC Wednesday to explain his company's role

Analyst Ratings

57%

of 7 ratings

Buy

57%

Hold

43%

Sell

EBS Earnings

-$0.12

$1.14

$2.41

$3.67

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

$3.19 per share

Actual

$3.67 per share

Replay Earnings Call